You have 9 free searches left this month | for more free features.

GB263T

Showing 1 - 25 of 3,440

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC, Other Solid Tumors Trial in Australia (GB263T)

Recruiting
  • NSCLC
  • Other Solid Tumors
  • GB263T
  • Saint Leonards, New South Wales, Australia
  • +3 more
Aug 3, 2022

Pancreatic Cancer Trial in ShangHai (TCR-T Cells Injection(GB3010 Cells Injection))

Recruiting
  • Pancreatic Cancer
  • TCR-T Cells Injection(GB3010 Cells Injection)
  • ShangHai, Shanghai, China
    Ruijin Hospital Affiliated to Shanghai Jiaotong University Schoo
Sep 19, 2023

Asthma Trial in Edegem (Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI, Reference product 1 (R1): CHF 5993 BDP/FF/GB

Recruiting
  • Asthma
  • Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI
  • +2 more
  • Edegem, Antwerpen, Belgium
    SGS Belgium NV - Clinical Pharmacology Unit
Jun 1, 2023

Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
  • Cincinnati, Ohio
  • +18 more
Jan 20, 2023

Severe Obesity Trial in Sweden (gastric bypass, Sleeve gastrectomy)

Active, not recruiting
  • Severe Obesity
  • gastric bypass
  • Sleeve gastrectomy
  • Tønsberg, Norway
  • +20 more
Sep 14, 2022

Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma Trial in Canada, United States (ABT-263)

Completed
  • Chronic Lymphoid Leukemia
  • +5 more
  • Los Angeles, California
  • +11 more
Jul 28, 2021

Peripheral T Cell Lymphoma Trial in Beijing (GB226)

Recruiting
  • Peripheral T Cell Lymphoma
  • GB226
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Mar 2, 2021

Global, Multicentre, Non Interventional Advagraf Conversion

Completed
  • Kidney Transplantation
  • Camperdown, New South Wales, Australia
  • +128 more
Nov 10, 2022

Advanced Hepatocellular Carcinoma Trial in Worldwide (Enzalutamide, Placebo)

Completed
  • Advanced Hepatocellular Carcinoma
  • San Francisco, California
  • +37 more
Feb 18, 2022

Warm Autoimmune Hemolytic Anemia (wAIHA) Trial in Worldwide (parsaclisinib, )

Recruiting
  • Warm Autoimmune Hemolytic Anemia (wAIHA)
  • Los Angeles, California
  • +52 more
Nov 15, 2022

Advanced Solid Tumors Trial in Worldwide (ASP8374, Pembrolizumab)

Completed
  • Advanced Solid Tumors
  • Scottsdale, Arizona
  • +53 more
May 18, 2022

Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Mar 8, 2022

Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in

Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • +3 more
  • Allogeneic Bone Marrow Transplantation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

HIV Trial in Worldwide (Darunavir (DRV) 800 milligram (MG) Oral Tablet, Ritonavir 100 MG Oral Tablet, N(t)RTIs)

Recruiting
  • HIV Infections
  • Darunavir (DRV) 800 milligram (MG) Oral Tablet
  • +6 more
  • Chennai, India
  • +6 more
Aug 30, 2021

Recurrent DLBCL, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Houston (drug, procedure, other, biological)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Steroid-Refractory Acute GVHD Trial in Worldwide (T-Guard, Ruxolitinib)

Terminated
  • Steroid-Refractory Acute Graft Versus Host Disease
  • Birmingham, Alabama
  • +47 more
Jan 22, 2023

Pulmonary Artery Hypertension Trial in Worldwide (GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler)

Active, not recruiting
  • Pulmonary Artery Hypertension
  • GB002 (seralutinib)
  • +2 more
  • Phoenix, Arizona
  • +64 more
Aug 17, 2022

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric

Active, not recruiting
  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
  • +3 more
  • Phoenix, Arizona
  • +219 more
Aug 16, 2022

Type 2 Diabetes Trial in Worldwide (Tirzepatide, Semaglutide)

Completed
  • Type 2 Diabetes
  • Birmingham, Alabama
  • +126 more
Jan 21, 2022

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic

Active, not recruiting
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 2, 2022

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

Recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 16, 2022

Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia

Recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 2, 2022

Leukemia, Acute Myeloid (AML) Trial in Worldwide (gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine)

Active, not recruiting
  • Leukemia, Acute Myeloid (AML)
  • Birmingham, Alabama
  • +125 more
Aug 9, 2022

Adrenal Androgens on Gender-typed Behavior in Girls With Turner

Not yet recruiting
  • Turner Syndrome
  • the correlation between level of adrenal androgen and gender-typed behavior in Girls with TS
  • Sohag, Egypt
    Sohag University Hospital
Apr 25, 2022

Helicobacter Pylori Infection Trial in Jinan (Tetracycline 500mg tid, Tetracycline 500mg qid)

Recruiting
  • Helicobacter Pylori Infection
  • Tetracycline 500mg tid
  • Tetracycline 500mg qid
  • Jinan, Shandong, China
    Department of Gastroenterology,QiLu Hospital,Shandong University
Mar 25, 2023